Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F21%3A10429764" target="_blank" >RIV/00216208:11110/21:10429764 - isvavai.cz</a>
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=zJUt-Xm10y" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=zJUt-Xm10y</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1212/WNL.0000000000010991" target="_blank" >10.1212/WNL.0000000000010991</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a
Popis výsledku v původním jazyce
Objective To compare the effectiveness of glatiramer acetate (GA) vs intramuscular interferon beta-1a (IFN-beta-1a), we applied a previously published statistical method aimed at identifying patients' profiles associated with efficacy of treatments. Methods Data from 2 independent multiple sclerosis datasets, a randomized study (the Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis [CombiRx] trial, evaluating GA vs IFN-beta-1a) and an observational cohort extracted from MSBase, were used to build and validate a treatment response score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. Results The overall ARR ratio of GA to IFN-beta-1a in the CombiRx trial was 0.72. The response score (made up of a linear combination of age, sex, relapses in the previous year, disease duration, and Expanded Disability Status Scale score) detected differential response of GA vs IFN-beta-1a: in the trial, patients with the largest benefit from GA vs IFN-beta-1a (lower score quartile) had an ARR ratio of 0.40 (95% confidence interval [CI] 0.25-0.63), those in the 2 middle quartiles of 0.90 (95% CI 0.61-1.34), and those in the upper quartile of 1.14 (95% CI 0.59-2.18) (heterogeneity p = 0.012); this result was validated on MSBase, with the corresponding ARR ratios of 0.58 (95% CI 0.46-0.72), 0.92 (95% CI 0.77-1.09,) and 1.29 (95% CI 0.97-1.71); heterogeneity p < 0.0001). Conclusions We demonstrate the possibility of a criterion, based on patients' characteristics, to choose whether to treat with GA or IFN-beta-1a. This result, replicated on an independent real-life cohort, may have implications for clinical decisions in everyday clinical practice.
Název v anglickém jazyce
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a
Popis výsledku anglicky
Objective To compare the effectiveness of glatiramer acetate (GA) vs intramuscular interferon beta-1a (IFN-beta-1a), we applied a previously published statistical method aimed at identifying patients' profiles associated with efficacy of treatments. Methods Data from 2 independent multiple sclerosis datasets, a randomized study (the Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis [CombiRx] trial, evaluating GA vs IFN-beta-1a) and an observational cohort extracted from MSBase, were used to build and validate a treatment response score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. Results The overall ARR ratio of GA to IFN-beta-1a in the CombiRx trial was 0.72. The response score (made up of a linear combination of age, sex, relapses in the previous year, disease duration, and Expanded Disability Status Scale score) detected differential response of GA vs IFN-beta-1a: in the trial, patients with the largest benefit from GA vs IFN-beta-1a (lower score quartile) had an ARR ratio of 0.40 (95% confidence interval [CI] 0.25-0.63), those in the 2 middle quartiles of 0.90 (95% CI 0.61-1.34), and those in the upper quartile of 1.14 (95% CI 0.59-2.18) (heterogeneity p = 0.012); this result was validated on MSBase, with the corresponding ARR ratios of 0.58 (95% CI 0.46-0.72), 0.92 (95% CI 0.77-1.09,) and 1.29 (95% CI 0.97-1.71); heterogeneity p < 0.0001). Conclusions We demonstrate the possibility of a criterion, based on patients' characteristics, to choose whether to treat with GA or IFN-beta-1a. This result, replicated on an independent real-life cohort, may have implications for clinical decisions in everyday clinical practice.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30103 - Neurosciences (including psychophysiology)
Návaznosti výsledku
Projekt
<a href="/cs/project/7H12016" target="_blank" >7H12016: Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2021
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Neurology
ISSN
0028-3878
e-ISSN
—
Svazek periodika
96
Číslo periodika v rámci svazku
2
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
14
Strana od-do
"e214"-"e227"
Kód UT WoS článku
000656634500012
EID výsledku v databázi Scopus
2-s2.0-85099774235